成人念珠菌血症持续阴性(1,3)-β-D-葡聚糖的临床意义与预后价值
该回顾性研究纳入2012-2017年某三级大学医院148例确诊念珠菌血症成人,比较血清BDG持续阴性者与任意阳性者的流行病学与临床结局。26/148(17.6%)患者BDG持续阴性,其微生物清除率更高、并发症更少、30天死亡率更低、住院更短,多因素分析显示持续阴性独立关联更好预后。
要点
- 念珠菌血症成人中约17.6%血清BDG持续阴性
- 持续阴性者并发症更少、30天死亡率更低、住院更短
- 持续阴性BDG或有助于个体化治疗管理
核心结论
- 念珠菌血症患者BDG持续阴性提示预后更好,可能反映系统性真菌负荷较低。
- 持续阴性BDG结果有望在未来辅助个体化治疗管理。
研究设计与样本
- 回顾性研究,纳入2012-2017年某三级大学医院确诊念珠菌血症成人148例。
- 纳入者需在真菌血症期间至少完成2次血清BDG检测(Fungitell Assay,阳性阈值≥80pg/mL)。
- 比较BDG全部阴性者与任意阳性者的流行病学与临床结局。
主要发现
- 26/148(17.6%)念珠菌血症成人BDG持续阴性。
- 持续阴性组3套血培养均生长念珠菌的比例低于阳性组(15.4% vs 45.1%;P = .005)。
- 持续阴性组中位Pitt评分低于阳性组(0[IQR 0-1] vs 1[IQR 0-2];P = .039)。
- 持续阴性组首次随访血培养微生物清除率高于阳性组(92.3% vs 69.7%;P = .005)。
- 持续阴性组念珠菌血症并发症少于阳性组(7.7% vs 33.6%;P = .008),30天死亡率低于阳性组(3.8% vs 23.8%;P = .004),住院时间短于阳性组(34天[IQR 18-55] vs 51天[IQR 35-91];P = .003)。
关键数值与推荐
- BDG阳性判定阈值为≥80pg/mL(Fungitell Assay)。
- 两组充分治疗比例相近(持续阴性组96.2% vs 阳性组93.4%;P = .599)。
- 多因素分析中BDG持续阴性独立关联更好预后(OR 0.12,95%CI 0.03-0.49;P = .003)。
临床怎么用
- 对念珠菌血症成人,可结合系列血清BDG结果判断真菌负荷与预后。
- BDG持续阴性者预后较好,但仍需按规范提供充分抗真菌治疗。
局限性
- 为单中心回顾性研究。
- 仅纳入至少完成2次血清BDG检测的患者,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The clinical relevance and the potential prognostic role of persistently negative (1,3)-β-D-glucan (BDG) in adults with proven candidemia is unknown. METHODS: This retrospective study included all adults diagnosed with candidemia our tertiary university hospital from 2012-2017 who had at least 2 serum BDG determinations throughout the episode of fungemia (Fungitell Assay; positive cut-off ≥80pg/mL). Epidemiology and clinical outcomes were compared between patients with all negative versus any positive BDG tests. Poor clinical outcomes included complications due to candidemia or 30-day all-cause mortality. RESULTS: Overall, 26/148 (17.6%) candidemic adults had persistently negative BDG tests. These patients were less likely to present Candida growth in all 3 sets of blood cultures (15.4% vs 45.1%; P = .005) and had less severe clinical presentations (median Pitt score, 0 [interquartile range {IQR} 0-1] vs 1 [IQR 0-2] in patients with any positive BDG test; P = .039). Although adequate treatment was equally provided to both groups (96.2% in persistently negative group vs 93.4 in positive group; P = .599), the persistently negative group had a higher rate of microbiological clearance in the first follow-up blood cultures (92.3% vs 69.7% in positive group; P = .005), fewer complications due to candidemia (7.7% vs 33.6% in positive group; P = .008), a lower 30-day mortality rate (3.8% vs 23.8% in positive group; P = .004), and a shorter in-hospital stay (34 days [IQR 18-55] vs 51 days [IQR 35-91] in positive group; P = .003). In the multivariate analysis, persistently negative BDG tests were independently associated with better prognoses (odds ratio 0.12, 95% confidence interval 0.03-0.49; P = .003). CONCLUSIONS: Candidemic patients with persistently negative BDG tests present a better prognosis than the comparative group, probably due to a lower systemic fungal burden. In this context, the appropriate use of persistently negative BDG results could be an aid to individualize therapeutic management in the near future.
引用
- Agnelli C, Bouza E, Del Carmen Martínez-Jiménez M, et al. Clinical Relevance and Prognostic Value of Persistently Negative (1,3)-β-D-Glucan in Adults With Candidemia: A 5-year Experience in a Tertiary Hospital. Clin Infect Dis. 2020. PMID: 31680136. doi:10.1093/cid/ciz555
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。